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Angelman syndrome (AS) is a neurological genetic disor-
der caused by loss of expression of the maternal copy of 
UBE3A in the brain. Due to brain-specific genetic imprint-
ing at this locus, the paternal UBE3A is silenced by a long 
antisense transcript. Inhibition of the antisense transcript 
could lead to unsilencing of paternal UBE3A, thus provid-
ing a therapeutic approach for AS. However, widespread 
delivery of gene regulators to the brain remains challeng-
ing. Here, we report an engineered zinc finger-based arti-
ficial transcription factor (ATF) that, when injected i.p. or 
s.c., crossed the blood–brain barrier and increased Ube3a 
expression in the brain of an adult mouse model of AS. 
The factor displayed widespread distribution through-
out the brain. Immunohistochemistry of both the hip-
pocampus and cerebellum revealed an increase in Ube3a 
upon treatment. An ATF containing an alternative DNA- 
binding domain did not activate Ube3a. We believe this 
to be the first report of an injectable engineered zinc fin-
ger protein that can cause widespread activation of an 
endogenous gene in the brain. These observations have 
important implications for the study and treatment of AS 
and other neurological disorders.
Received 3 November 2015; accepted 22 December 2015; advance online 
publication 2 February 2016. doi:10.1038/mt.2015.236
INTRODUCTION
Angelman syndrome (AS) is a neurological disorder of genetic 
origin that affects ~1:15,000 births and is characterized by intellec-
tual disabilities, lack of speech, ataxia, and seizures.1,2 The genetic 
cause of AS is loss of UBE3A (ubiquitin-protein ligase E6-AP) 
expression in the brain, usually due to a 4-Mb de novo deletion 
of the maternal 15q11–q13 region, but also caused by imprint-
ing defects, paternal uniparental disomy, or point mutations in 
the maternal UBE3A allele.3,4 Due to brain-specific imprinting, the 
paternal allele is silenced, thus loss of the maternal allele causes 
UBE3A deficiency throughout the brain.5,6
A traditional gene therapy approach using adeno-associated 
virus and cDNA to restore Ube3a expression in the brain of a 
mouse model of AS resulted in a partial rescue of learning and 
memory defects but not motor coordination.7 These results may 
be explained by the limited distribution of viral vectors in the 
brain. Other approaches have attempted to reactivate (“unsi-
lence”) the paternal Ube3a allele, with varied success for molecu-
lar and phenotypic rescue. Paternal silencing is caused by a long 
 brain-specific RNA transcript that overlaps and is antisense to 
Ube3a (Ube3a-ATS; Figure  1a). The initiation, splicing, and 
function of this transcript are complex. The promoter of the 
Snurf/Snrpn locus is one start site for the Ube3-ATS, but numerous 
upstream start sites and exons create transcripts that, in mouse, 
can be over 1,000 kb.8 Inhibiting the extension of this transcript by 
insertion of a transcriptional termination sequence,9 topoisomer-
ase inhibitor drugs,10 or antisense oligonucleotides11 results in par-
tial unsilencing of paternal Ube3a, and some phenotypic rescue. 
These previous studies support that inhibition of Ube3a-ATS is a 
valid strategy to enhance paternal Ube3a expression.
In this study, we designed artificial transcription factors 
(ATFs) with the goal of increasing paternal expression of Ube3a in 
the brain of an adult mouse model of AS. ATFs are composed of a 
programmable DNA-binding domain, such as zinc fingers, TALEs 
or CRISPR/Cas systems, and an effector domain that can activate 
or repress transcription.12,13 Zinc finger-based ATFs have been 
evaluated in phase 2 clinical trials (NCT00476931), which dem-
onstrated that zinc finger ATFs could be well tolerated in human 
subjects. The lack of similar data for TALE and CRISPR ATFs led 
us to choose zinc fingers for our initial studies. However, delivery 
of such ATFs throughout the brain has remained an unmet chal-
lenge. In particular, the blood–brain barrier created by the vascu-
lar endothelium in the central nervous system limits the method 
of delivery for most viral vectors, biologics, and drugs to i.c. or i.t. 
injection, which may be unfavorable for repeated treatments. Since 
ATFs only provide transient gene regulation they would need to 
be administered on a regular schedule to be effective for long-term 
gene regulation. In this study, we explored an alternative delivery 
approach utilizing an HIV TAT cell-penetrating peptide, which 
has been shown capable of delivering large proteins to the entire 
brain from a single i.p. injection.14,15 We observed that a purified, 
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TAT-linked, zinc finger-based ATF repression protein targeted to 
the Snurf/Snrpn promoter was able to be injected i.p. or s.c., cross 
the blood–brain barrier, and activate endogenous Ube3a expres-
sion in multiple brain regions of a maternally Ube3a-deficient 
mouse model of AS.16 Such an approach could eventually be useful 
for the treatment of AS and other neurological conditions.
RESULTS
Highly active zinc finger ATFs were identified by 
luciferase assay
In principle, activation of paternal Ube3a can be achieved either 
by super activation of the Ube3a promoter or by repression of 
the inhibitory Ube3a-ATS transcript. Eleven zinc finger arrays 
Figure 1 ATF targeting strategy and binding results. (a) Top: ATFs are shown in relationship to the genomic region on the mouse chromosome 7. 
Imprinting in this region results in genes with paternal-only, maternal-only, or silenced expression (active genes, filled; silenced genes, open). Genes 
outside this region are biallelically expressed. In the Angelman syndrome mouse model used in these studies, a targeted insertion with a stop codon 
replaces exon five (coding exon 2) of the maternal Ube3a (black X). U-exons, upstream exons of the Ube3a-ATS; PWS-IC, Prader–Willi syndrome 
imprinting control region either methylated (filled circle) or unmethylated (open circle). Bottom: Luciferase assays of 11 ATFs in HEK293T cells. Bars 
indicate the firefly luciferase signal, normalized to renilla luciferase control. Error bars indicate SD. *P < 0.01; two-tailed heteroscedastic t-test, rep-
resenting three biological replicates. (b) Representative electromobility shift assay of S1 ZF array binding its target. (c) In vitro binding motif of the 
TAT-S1 ATF determined by Bind-n-Seq analysis. The sequence of the S1 target site is below. The motif represents a 56-fold enrichment over random 
background, P < 0.001, one-tailed Fisher’s Exact Test. (d) ChIP–PCR data for the HA-tagged ATF S1 or EV at the S1 chromosomal target site in mouse 
Neuro2A cells. IgG serves as a negative control. The graph shows ChIP-enrichment relative to 0.1% chromatin input. ATF, artificial transcription factor; 
ChIP, chromatin immunoprecipitation; EV, empty vector; IFN, interferon; ZF, zinc finger.
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consisting of six zinc finger modules each were constructed to 18-bp 
target sites (Supplementary Table S1), including four to a region 
upstream of the Ube3a locus, three upstream of the Snurf/Snrpn 
locus (thought to be an initiation site of the Ube3a-ATS17), two to 
sites common in the approximately nine upstream initiation sites of 
the Ube3a-ATS,8 and two to a region between the Snord115 cluster 
and Ube3a (Figure 1a, top). Activating factors contained a VP64 
transcriptional activation domain18 and were assayed in HEK293T 
cells using a reporter plasmid in which luciferase was driven by the 
Ube3a promoter (considered to be a 1,000-bp region upstream of 
the transcriptional start site). Repressing factors contained a KRAB 
transcriptional repression domain18 and were assayed using lucifer-
ase reporter plasmids that harbored the target sites upstream of an 
SV40 promoter. The factor that provided the most robust activation 
was A8, and the two factors that produced the most potent repres-
sion regulatory effect (>fivefold repression, P < 0.015) were SR71 
and S1 (Figure 1a, bottom, >fivefold regulation, P < 0.01).
Creation of a purified fusion ATF protein for i.p. or 
s.c. injections
To investigate the potential of an injected ATF to regulate an 
endogenous gene in the brains of mice, we constructed fusion 
proteins for the most efficient regulators S1, SR71, and A8. These 
fusions contained an N-terminal maltose-binding protein for 
purification, a cell-penetrating peptide consisting of the 10-aa 
transduction domain of the HIV-transactivator protein (TAT, res-
idues 48–5719), mCherry red fluorescent protein to aid in protein 
solubility and visualization, an HA epitope tag for detection, and 
an SV40 nuclear localization signal to ensure nuclear delivery. The 
TAT cell-penetrating peptide had been previously used to deliver 
proteins to the brains of mice following i.p. injection.20 The KRAB/
VP64 domain was appended to the C-terminus of the zinc finger 
protein giving rise to TAT-S1, TAT-SR71, and TAT-A8 (Figure 2a 
and Supplementary Figure S1). Of these three constructs, only 
TAT-S1 was able to be purified in sufficient quantity (mg) for 
multiple mouse injection studies (data not shown). An electromo-
bility shift assay (EMSA) demonstrated that S1 zinc finger array 
bound its target with an affinity of 5 ± 1.5 nmol/l (Figure 1b). The 
EMSA was repeated with the TAT-S1 and showed similar affinity 
of 8 ± 1.5 nmol/l (data not shown). The binding preference of the 
TAT-S1 was investigated using the in vitro Bind-n-seq assay, in 
which the protein was incubated with oligonucleotides represent-
ing all possible 21-bp binding regions, and the preferred targets 
were identified by next-generation sequencing.21 The observed 
binding motif indicated a high specificity for the intended tar-
get sequence (Figure  1c, 56-fold enrichment over background, 
P < 0.001).To evaluate S1 binding to the target locus in vivo, we 
performed chromatin immunoprecipitation followed by PCR in 
mouse Neuro2A cells. The S1 zinc finger array bound strongly to 
its intended chromosomal target site in vivo, while no binding was 
observed at an unrelated promoter (Figure 1d). Thus, the TAT-S1 
showed substantial affinity and specificity for its target site.
Injected TAT-ATFs distribute widely in mouse 
including the brain within 4–8 hours
To confirm that the upregulation of Ube3a was due specifically to 
TAT-S1, a negative control construct was made with zinc finger 
array R6 that was not designed to bind at the Snurf/Snrpn locus 
(chromosome 7). The closest match in the mouse genome con-
tained two mismatches and was >30,000 bp from the nearest gene 
on chromosome 6. TAT-S1 and TAT-R6 differ by only 26 aa in 
their DNA-binding domains. The 922-aa TAT-ATFs (S1 and R6) 
were expressed in Escherichia coli using a cold temperature induc-
tion (see Materials and Methods) and purified (Supplementary 
Figure S2). Injection of adult wild-type C57BL/6 mice with puri-
fied TAT-S1 and TAT-R6 (160–200 mg/kg, i.p.) produced a signifi-
cant peak of mCherry fluorescence in the brain within 4–8 hours 
(P < 0.005; Figure 2b,c). Full-length TAT-ATF protein could be 
detected by western blot analysis of brain nuclear lysates, in addi-
tion to potential lower molecular weight breakdown products 
(Figure 2d). TAT-ATFs also distributed to other parts of the body 
(Figure  3), although lysates of these organs did not show any 
Figure 2 Distribution of TAT-S1 and TAT-R6 in adult mouse brain. 
(a) Structure of TAT-S1 and TAT-R6 ATF proteins. (b) mCherry fluores-
cence/ambient light merged image of live Ube3a-deficient mice 4 hours 
postinjection with TAT-S1, ATF injection buffer (Mock), or the negative 
control TAT-R6 (0.16–0.20 g/kg, i.p.). Fur was shaved to improve the 
fluorescent signal. (c) Kinetics of fluorescence in the C57BL/6 brains 
for  TAT-S1 (green triangles), Mock (red squares), and TAT-R6 (blue dia-
monds). *P < 0.005 compared to Mock at that timepoint, two-tailed 
homoscedastic t-test, n = 5. (d) Western blot detecting the HA tag in 
brain nuclear lysate 4 hours postinjection. Filled arrow, 100-kD full-
length protein band. Potential lower molecular weight breakdown prod-
ucts containing the HA tag are also visible. ATF, artificial transcription 
factor; M, mock injection; MBP, maltose-binding protein; NT, no treat-
ment; S1, TAT-S1; R6, TAT-R6; ZF, zinc finger.
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detectable full length TAT-ATF (data not shown). The data sug-
gest that TAT-ATFs injected i.p. can cross the blood–brain barrier 
and enter nuclei in the cells of the brain.
Injected TAT-S1, but not TAT-R6, increases 
endogenous Ube3a expression in the brains of AS 
mice
To investigate if TAT-S1 could perform its gene regulatory function 
in the brains of mice, we used the Jiang et al.16 mouse model of AS 
that carried a transgene insertion in exon 5 (coding exon 2) at the 
5′ end of the maternal Ube3a gene (AS mice, see Figure 1a). The 
insertion causes strong attenuation of Ube3a protein expression 
from the maternal allele. Adult mice (≥2 months) were used for 
these experiments since the Ube3a-ATS would be fully expressed 
from the paternal allele22 and would more accurately reflect an 
age of human diagnosis (3–4 years old), unlike genetic crosses or 
early postnatal interventions. Based on the  anti-Ube3a-ATS stud-
ies described earlier,9–11 we expected our TAT-S1 to activate Ube3a 
protein expression from the paternal allele in this mouse model. 
However, given the half-life of our protein’s signal in the brain is 
between 8 and 24 hours, and the KRAB effector domain is known 
to provide only transient transcriptional repression,23 we reasoned 
that multiple administrations are necessary to ensure sufficient 
presence of the ATF over time to alter gene expression patterns. 
The ATFs were injected (160–200 mg/kg, s.c.) three times per 
week for 4 weeks (Figure  4a). A final injection was given four 
hours before harvest to examine distribution of the ATF.
We observed no overt signs of toxicity during the 4-week 
treatment period, based on normal appearance and behaviors of 
the mice and no visual organ pathology upon dissection (data not 
shown). We observed widespread distribution of ATFs throughout 
all regions of the brain (Figure 4b). Ube3a protein was found to 
be significantly increased in AS mice treated with TAT-S1, but not 
TAT-R6, in both hippocampus and cerebellum (P < 0.01, n = 3–4 
mice; Figure 4c,d). The upregulation of Ube3a was confirmed by 
western blot analysis of brain cytosolic lysates from three different 
mice that received TAT-S1 treatment (Figure 4e). In the western 
blot, the treatment-dependent appearance of a particular Ube3a 
isoform (the lower band) can be clearly seen. Both the immu-
nohistochemistry and western blot confirm that the treatment 
increased Ube3a to a level intermediate between no-treatment AS 
and wild-type control mice. These results were replicated in an 
additional experiment in which the treatment was administered 
by i.p. injection for 7.5 weeks and visualized using a different anti-
body to Ube3a (Supplementary Figure S3).
DISCUSSION
Our study demonstrates that purified TAT-S1 protein can be 
injected s.c. or i.p. in AS mice, cross the blood–brain barrier, enter 
neurons throughout the brain, and alter the expression of Ube3a. 
We believe this to be the first report of an injectable engineered 
zinc finger repressor that can distribute widely in the brain and 
regulate the expression of an endogenous gene. Distribution of 
ATFs was observed by in vivo mCherry fluorescence throughout 
the body of the mouse, including the cranium. Widespread distri-
bution in the brain was also confirmed by immunofluorescence 
based on a different part of the protein, the HA tag. Furthermore, 
we demonstrated that the full-length ATF is able to penetrate 
nuclei in cells of the brain (Figure 2d). TAT-S1 was able to signifi-
cantly increase Ube3a expression in both the hippocampus and 
cerebellum, indicating that the portion of the protein necessary 
for Ube3a-ATS repression entered the nuclei of cells in the brain. 
While TAT-S1 must be nuclear to activate Ube3a expression, the 
Ube3a protein is not necessarily expected to be nuclear. The two 
anti-Ube3a antibodies used in the current study detected primar-
ily the cytoplasmic form. Previous publications have noted that 
different isoforms of Ube3a localize to the nucleus, the cytoplasm 
or both,24 and roles have been proposed for Ube3a at synaptic 
junctions.25
The mechanism of TAT-mediated delivery of large proteins 
was reported to be adsorptive endocytosis.26 Although formally 
this study did not demonstrate that delivery was TAT-dependent, 
adsorptive endocytosis would likely allow the protein to enter 
many cell types, including both neurons and glia in the brain. 
However, the Ube3a-ATS is not expressed in glia, in these cells 
Ube3a is always expressed from both the maternal and paternal 
alleles. The fact that TAT-S1 upregulated Ube3a strongly sug-
gests that the factors entered neurons, as this is where Ube3a is 
imprinted by the Ube3a-ATS, the target of TAT-S1. The observa-
tion that Ube3a expression was increased by TAT-S1 but not TAT-
R6, which differed by only 26 aa in their DNA-binding domains, 
indicates that the function of TAT-S1 was dependent on the DNA-
binding specificity of its zinc finger array. We note that the pres-
ence of the maltose-binding protein band in the injected material 
did not appear to influence the results, as both the TAT-S1 and 
TAT-R6 samples contained this band but only  TAT-S1 increased 
Figure 3 Artificial transcription factor distribution in other organs. (a) mCherry fluorescence/ambient light merged image of mice harvested 
4 hours postinjection with TAT-S1, injection buffer (Mock), or TAT-R6 (0.16–0.20 g/kg, i.p.). The skin on the back was removed to improve the 
fluorescent signal. Intense signal can be seen in the kidneys. (b) Internal organs harvested after 4 hours. Note that the bright white kidney in the 
 TAT-R6-injected sample indicates fluorescence in excess of the maximum setting.
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Ube3a. Therefore, increased Ube3a expression was not caused by 
potential nonspecific factors such as stress or potential immune 
response in the mouse, contaminants in the injection solution, or 
nontargeted actions by other parts of the protein such as detach-
ment of the KRAB domain.
In this study, S1 treatment only partially restored Ube3a expres-
sion to wild-type levels. This intermediate level was expected since 
previous therapeutic approaches using topoisomerase inhibitors, 
antisense oligonucleotides, and stop codon insertions had resulted 
in partial restoration of Ube3a from the paternal allele.9–11 TAT-R6 
Figure 4 Reactivation of Ube3a in a mouse model of AS by TAT-S1 but not TAT-R6. (a) Artificial transcription factors were injected (160–200 mg/
kg, s.c.) three times per week for 4 weeks, with the final inject 4 hours before harvest. (b) TAT-S1 distribution in a whole brain sagittal section (HA, 
5 µm) from wild-type mice receiving NT or TAT-S1. White dashed line indicates outline of brain section. Images were not altered. (c) Imaging of 
Ube3a protein expression (green) or DAPI (blue) in brain slices of the hippocampus and cerebellum (Ube3a (Sigma E8655), 50 µm). Sections from 
NT wild-type and AS mice are shown as controls. A 10% linear brightness reduction was applied equally to the green channel of all images to reduce 
autofluorescence and clarify features. (d) Quantification of Ube3a from unaltered images of the same regions in different mice. One-way analysis 
of variance found significant difference between groups (F(3,18) = 15.5, P < 0.0001), n = 3–4 mice. *P < 0.01, post hoc Tukey–Kramer honest sig-
nificant difference. (e) Western blot of Ube3a from brain cytosolic lysates of three different mice that received the indicated treatment (α-Ube3a, 
Sigma E8655). Red arrow indicates isoform that is specific to both the WT and TAT-S1-treated mice, but absent in the AS NT controls. Ponceau 
S staining of the membrane is shown as a loading control. AFI, average fluorescence intensity; AS, Angelman syndrome; CB, cerebellum; DAPI, 
 4′,6-diamidino-2-phenylindole; HC, hippocampus; M, medulla; NT, no treatment; WT, wild type.
Injection time line (days)
90
70
α
-
Ub
e3
a 
(A
FI)
50
30
NT TAT-R6 TAT-S1
kD
WT NT AS NT AS TAT-S1
100
80
α
-
Ub
e3
a*
*
WT P
o
n
ce
a
u
1 8 15
Hippocampus Cerebellum
22 29
a
c
b
d e
552 www.moleculartherapy.org vol. 24 no. 3 mar. 2016
© The American Society of Gene & Cell Therapy
ATF Unsilences Ube3a in Mouse Brain
appeared to cause a slight, but not significant, decrease in Ube3a lev-
els in the experiment shown in Figure 3, but a slight, but not signifi-
cant, increase in the experiment shown in Supplementary Figure 
S3. These fluctuations are likely due to experimental variation using 
different cohorts on different days. In the current study, the par-
tial reactivation by TAT-S1 may have been caused by an insuffi-
cient concentration of TAT-S1 at the target site. Future experiments 
could increase either the dose or the timing of administrations. The 
partial response might also be due to additional Ube3a-ATS tran-
scripts initiating from upstream promoters.8 Future experiments 
could examine additional ATFs that would inhibit these promoters 
and perhaps be delivered as a combinational therapy.
The prospect for long-term treatment with proteins has been 
demonstrated by insulin and numerous other biologics.27 In principle, 
the use of ATF biologics with short-term effects similar to drugs may 
have advantages over approaches such as permanent gene engineer-
ing, for which distribution, dosage and reversibility are problematic.12 
The Ube3a-ATS transcript is only expressed in mature neurons of the 
brain (reviewed in ref. 28); therefore, we do not expect that TAT-S1 will 
affect Ube3a expression in  non-neuronal cells. No overt toxicity was 
observed over a 4-week treatment period in the current study. Longer-
term studies might reveal innate or adaptive immune responses to the 
treatment. ATFs designed to alter epigenetic information may eventu-
ally provide more persistent gene regulatory effects,29,30 reducing costs 
and potential immune risks. Methods that restrict delivery to neurons 
only may help reduce amount of protein required. In addition, other 
programmable platforms such as TALE and CRISPR/Cas systems may 
be useful for gene regulation in the brain, even as purified protein.31,32 
The development of an ATF approach could have significant impact 
beyond AS, since in other neurological disorders, only small adjust-
ments to the DNA-binding domain of the ATF would be required 
to target disease-related loci that are imprinted (Rett, Prader–Willi), 
dominant (Huntington), or haploinsufficient (22q11.2 deletion, Pitt-
Hopkins, and many autism spectrum disease genes).
MATERIALS AND METHODS
In vitro transcription factor assays. Zinc finger coding regions were 
designed by modular assembly methods33 and synthesized by BioBasic 
(Markham, Canada). The arrays were cloned using XhoI and NotI into 
the PGK promoter-driven mammalian expression vector pPGK-VP64,34 
which appended an N-terminal HA epitope tag and SV40 nuclear local-
ization sequence, and either a C-terminal VP64 transcriptional activation 
domain18 or a KRAB transcriptional repression domain, cloned at the NotI 
and PstI sites.18 Recognition helices of the zinc finger arrays are provided in 
Supplemental Table S1. Target sites for the ATFs were cloned between NotI 
and XhoI sites upstream of the SV40 promoter in pGL3-control plasmids 
(Promega, Madison, WI), as listed in Supplementary Figure S1. In 24-well 
plates, HEK293T cells at 80% confluency in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum, 1 U/ml of penicillin, and 
1 µg/ml of streptomycin were cotransfected with 100 ng of ATF expression 
plasmid, 25 ng of modified pGL3-control firefly luciferase reporter plasmid 
containing ATF target sites, and 25 ng of pRL-TK-Renilla Luciferase plasmid 
(as a transfection control, Promega), using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). Cells were harvested 48 hours posttransfection by remov-
ing media, washing with 500 µl of 1× Dulbecco’s phosphate-buffered saline 
(Life Technologies, Carlsbad, CA), followed by lysis in 100 µl of 1× Passive 
Lysis Buffer (Promega) with 1× Complete Protease Inhibitors (Roche, Basel, 
Switzerland). Clarified cell lysates (20 µl) were used to determine luciferase 
activity using DualGlo reagents (40 µl, Promega) in a Veritas microplate 
luminometer (Turner Biosystems, Sunnyvale, CA). The firefly luciferase 
signal was normalized to renilla luciferase controls. All experiments were 
performed in duplicate and repeated on 3 different days. 
Expression of TAT-S1 and TAT-R6 protein. TAT-ATF coding regions were 
cloned into the pMAL-c2X vector (New England Biolabs, Ipswich, MA) 
between EcoRI and HindIII. The full sequence of the TAT-S1 protein is pro-
vided in Supplemental Figure S1, and the recognition helices of TAT-R6 are 
provided in Supplemental Table S1. Proteins were expressed in NEB5α E. 
coli (New England Biolabs) by inoculating 5 ml overnight cultures into 800 ml 
of Luria Broth medium (Sigma, St Louis, MO) with 50 µg/ml Carbenicillin. 
Cultures were shaken overnight at 37 °C, then moved to 4 °C, and induced 
with isopropyl β-d-1-thiogalactopyranoside (0.5 mmol/l) and gently shaken 
for 48–72 hours. The cold temperature induction was critical to obtaining 
high yields; induction at room temperature or 37 °C was far less efficient. 
The culture was pelleted and resuspended in 30 ml of Zinc Buffer A (ZBA; 10 
mmol/l Tris (pH 8.5), 90 mmol/l KCl, 1 mmol/l MgCl2, 100 µmol/l ZnCl2). The 
resuspended pellet was microfluidized, which was critical for obtaining full-
length protein. Microfluidized lysates were run over columns of amylose resin 
(New England Biolabs, E8021L) that had been prepared by washing twice 
with deionized water, twice with Column Buffer (20 mmol/l Tris–HCl (pH 
7.4), 0.2 mol/l NaCl, 1 mmol/l ethylenediaminetetraacetic acid (EDTA)) and 
twice with ZBA. Protein was eluted in Elution Buffer (ZBA, 500 mmol/l malt-
ose) and concentrated to ~16 mg/ml using a Centricon Plus-70 (Millipore, 
Billerica, MA, UFC710008). Proteins were sterile filtered to remove any 
residual bacteria and routinely checked to assure no detectable endotoxins 
were present. Protein integrity was evaluated using Coomassie-stained gels 
and concentration established via Nanodrop A280 UV absorption. Protein 
concentrations for injections refer to the  full-length + maltose-binding pro-
tein band intensities, of which only half was considered to be the 100-kD full-
length protein (Supplementary Figure S2). Proteins were stored at −80 °C in 
ATF Injection Buffer (Elution Buffer, 30% glycerol, 4 mmol/l dithiothreitol). 
A dose of 160–200 mg/kg consisted of a 0.25 ml injection i.p. or s.c. containing 
4 mg of total protein in a 20–25 kg mouse.
Electromobility shift assays. Biotin-labeled DNA targets were generated by 
PCR-amplification using a 5′ biotinylated forward primer of 69-mer oligonu-
cleotides containing 18-base pair zinc finger target site (Supplementary Table 
S2). PCR reactions contained unlabeled reverse primer in a 4:1 ratio over the 
biotinylated primer. Amplified targets were column purified (Qiagen, Hilden, 
Germany). Protein–DNA complexes were mixed on ice and then incubated 
in the dark for 1.5 hours at room temperature in ZBA, 0.05% NP-40, 0.1 mg/
ml bovine serum albumin, 10% glycerol, and 35–75 pmol/l target oligo. 
Protein–DNA complexes were separated from the unbound probe using 
7% polyacrylamide Tris/boric acid/EDTA gels run in 0.5× Tris/boric acid/
EDTA (BioRad, Hercules, CA) and then transferred onto Biodyne B nylon 
membranes. Complexes were UV cross-linked to the membranes for 4 min-
utes (UV Stratalinker 1800, Agilent, Santa Clara, CA). The biotinylated DNA 
was visualized using the LightShift Chemiluminescent EMSA Kit (Pierce, 
Waltham, MA) according to the manufacturer’s protocol. Equilibrium bind-
ing constants (apparent KD) were calculated from protein titration experi-
ments. Gel images on X-ray film (Denville Scientific, South Plainfield, NJ) 
were scanned and then quantitated using ImageJ. All reported EMSA mea-
surements were averages of at least three experiments performed with inde-
pendent protein dilutions. Representative data are shown in Figure 1b.
Chromatin immunoprecipitation assay.  The mouse neuroblastoma cell 
line Neuro2a (ATCC #CCL-131) was grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% bovine calf serum. Neuro2a cells were 
grown to 70% confluency and transfected with 15 µg S1-KRAB-expressing 
plasmid per 10-cm dish using Lipofectamine 2000 (Life Technologies). Cells 
were cross-linked 48 hours posttransfection by incubation with 1% form-
aldehyde solution for 10 minutes at room temperature. Chromatin immu-
noprecipitation assays were performed as previously described with minor 
modifications.35 About 30 µg of sonicated chromatin was incubated with 3 
µg of monoclonal anti-HA antibody (Covance, San Diego, CA, HA.11 clone 
Molecular Therapy vol. 24 no. 3 mar. 2016 553
© The American Society of Gene & Cell Therapy
ATF Unsilences Ube3a in Mouse Brain
16B12), monoclonal anti-RNA Polymerase II antibody (Covance 8WG16), 
or control mouse IgG (Sigma). Immunoprecipitates were captured using 
3 µg rabbit anti-mouse serum and StaphA cells (Sigma). After washes and 
reversal of DNA–RNA–protein cross-links, standard and quantitative PCR 
were performed to confirm specific binding to the S1 target sequence in 
chromatin immunoprecipitation samples as compared to 0.1% input con-
trol or relative to binding at an unrelated promoter on chromosome 4. All 
primer sequences are listed in Supplementary Table S2. Primers Snurf-F 
and Snurf-R to the mouse Snurf gene promoter target site were used as posi-
tive control primers, while mmchr4-F and mmchr4-R to a region on mouse 
chromosome 4 served as a negative control. Specific fragments were ampli-
fied using GoTaq (Promega) DNA polymerase (2 minutes at 95 °C; 30 sec-
onds at 95 °C, 30 seconds at 60 °C, 30 seconds at 72 °C, 35 cycles; 5 minutes 
at 72 °C). PCR products were separated on a 1.5% agarose gel and visualized 
using the Gel Doc XR+ System (BioRad). Quantitative real-time PCR was 
used to calculate binding enrichment using the ΔΔCt method.
Bind-n-Seq assay. Bind-n-Seq was performed essentially as previously 
described.21 Briefly, we used barcoded 93-mer double-stranded oligo-
nucleotide targets containing Illumina (San Diego, CA) primer binding 
sites and a 21-nt random region. Various protein concentrations were 
incubated with 3 µmol/l oligo target, 0.12 µg/µl herring sperm DNA, 100 
µmol/l ZnCl2, 5 mmol/l dithiothreitol, 1% bovine serum albumin, 5% glyc-
erol, and 1, 50, or 100 mmol/l KCl. Bound complexes were precipitated 
using amylose resin and then washed with a corresponding buffer of 10 
mmol/l Tris pH 8.5, 100 µmol/l ZnCl2, 1 mmol/l MgCl2, 5 mmol/l dithio-
threitol, and 1, 50, or 100 mmol/l KCl. Eluted and amplified DNA was 
sequenced on an Illumina HiSeq2000 or MiSeq. Motifs were determined 
using MERMADE, available at korflab.ucdavis.edu/Datasets/BindNSeq/.
Mice. All mice were maintained and experiments conducted according to 
University of California, Davis approved Institutional Animal Care and 
Use Committee (IACUC) guidelines and protocols. The AS mouse model16 
was obtained from Jackson Laboratories (Bar Harbor, ME, Stock 004477, 
129-Ube3atm1Alb/J) and maintained on a mixed background of SV129 and 
C57BL/6.  Wild-type C57BL/6 mice (Jackson Laboratories) and SV129 mice 
(Charles River Laboratories, Wilmington, MA) were used for matings with 
Ube3a-deficient female mice. Genotyping was performed according to the 
supplier’s protocol, with the modification that the annealing temperature 
was changed to 60 °C. Primers are listed in Supplementary Table S2. All 
animals receiving injections were older than 2 months of age at the time of 
the first injection.
Maestro in vivo imaging of mice. All mice used in the initial blood–brain 
barrier study were C57BL/6 male mice. All mouse images were performed 
on a Maestro 2 Imager (PerkinElmer, Waltham, MA), use and training pro-
vided by the Center for Molecular and Genomic Imaging at UC Davis. The 
green filter was used with acquisition settings of 550–800 nm in 10-nm steps. 
Before injections, an image was taken of the purified protein using the auto-
expose option. Timepoints used were 15 minutes, 4 hours, 8 hours, and 24 
hours postinjection. At each timepoint, fluorescent images were taken of the 
injection site, the head and the back. Exposure times for the injection site, 
head, and back images were established from a previous pilot experiment at 
229, 1,959, and 1,986 ms, respectively. On all images, a mock-treated animal 
served as a control, mock was the ATF/protein elution buffer of ZBA, 500 
mmol/l maltose. All images were based on the same raw inputs for mCherry 
signal and background mouse signal. Analysis of mCherry signal was per-
formed by measuring the mCherry by using a consistent sized area in the 
brain region using Maestro software. The measurement area was the same 
for each mouse across all treatments. Additional later images were taken of 
the Ube3a-deficient mice when treated, to ensure brain localization of the 
TAT-ATFs.
Immunohistochemistry. For the images in Figure 4b,c (50-µm-thick sec-
tions), one brain hemisphere was washed in 1× TBS (50 mmol/l Tris–Cl, 
pH 7.5, 150 mmol/l NaCl), fixed in 10% buffered paraformaldehyde 
overnight, and then placed into 30% sucrose for 3 days. Following brain 
saturation, the tissue was frozen in Tissue-Tek CRYO-OCT Compound 
 (Thermo-Fisher, Waltham, MA, 14-373-65) and then sectioned on a 
Leica (Nussloch, Germany) cryotome. Blocking was performed using 
Superblock (Life Technologies) for 1 hour, followed by a 10% goat 
serum, 0.3% Triton X in 1× TBS for 2 hours. Following aspiration, 
slides were stained with primary anti-HA 1:150 (Roche 12013819001) 
that was directly labeled with an Apex Antibody labeling kit (Life 
Technologies, A10470), or anti-Ube3a 1:100 (Sigma E8655) labeled with 
the Apex Antibody labeling kit, in 5% goat serum and 0.15% Triton X 
and incubated at 4 °C overnight. Slides were washed three times with 
1× TBS, stained with 4′,6-diamidino-2-phenylindole for 10 minutes, 
washed three times with 1× TBS, and then mounted with coverslip using 
Prolong Gold (Life Technologies). Images were acquired using a Leica 
DM6000B epifluorescent microscope. A 10% linear reduction in bright-
ness was applied equally to the green channel of all images to reduce 
autofluorescence and clarify features. All fluorescence intensity measure-
ments were performed on unaltered images using ImageJ software 1.48v. 
Fluorescence intensities were measured in the hilus region of the dentate 
gyrus in the hippocampus and the Purkinje cell layer in the cerebellum.
For the images in Supplementary Figure S3 (5-µm sections), paraffin 
embedding was utilized. One hemisphere of the brain was placed in 1× TBS 
and then fixed in 4% paraformaldehyde overnight. Brains were fixed in an 
additional 3 hours in 10% paraformaldehyde solution and then placed into 
wax for sectioning. Slides of these sectioned tissues were incubated overnight 
at 56 °C, washed with xylene twice for 10 minutes, and then soaked in 100% 
ethanol twice for 10 minutes. Antigen retrieval was performed using 1× 
Target Retrieval Solution (Dako, Carpinteria, CA) at 95 °C for 1 hour and 
then washed in 1× SSC (150 mmol/l NaCl, 15 mmol/l Sodium Citrate) 
at room temperature for 5 minutes while rocking gently. Blocking was 
performed using Superblock for 1 hour, followed by a 10% goat serum, and 
0.3% Triton X in 1× TBS for 2 hours. Following aspiration, slides were stained 
with primary anti-Ube3a 1:1,000 (Atlas, Stockholm, Sweden, HPA039410) 
with coverslip and incubated at 4 °C overnight. Coverslip were removed 
and the slide was washed three times with 1× TBS. The secondary antibody, 
goat-anti-rat Alexa Fluor 647 1:1,000 (Abcam, Cambridge, MA, 150159) or 
goat-anti-rabbit Alexa Fluor 488 1:1,000 (Abcam 150077) in 1× TBS, 5% 
goat serum, and 0.15% Triton, was applied for 2 hours, the slides were then 
washed three times with 1× TBS, and then dried before placing coverslips. 
Coverslips were applied with 4′,6-diamidino-2-phenylindole-containing 
Vectashield (Vector Laboratories, Burlingame, CA, H-1200). The images in 
Supplementary Figure S3 received no alterations. All fluorescence intensity 
measurements were performed on unaltered images as above.
Western blot. For the experiments in Figure 2d, one hemisphere from each 
brain was flash frozen in liquid nitrogen. Tissues were treated first with 
hypotonic buffer (2 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) (pH 5), 1 mmol/l KCl, 0.1 mmol/l EDTA, 10% Glycerol, 1× 
protease inhibitor cocktail (Roche, 11873580001), 50 µmol/l phenylmeth-
ylsulfonyl fluoride, 50 µl of 100 µmol/l dithiothreitol, in diethylpyrocarbon-
ate-treated water) and then ground with motorized pestle for 35 seconds. 
The remaining nuclear pellet after centrifugation was lysed with radioim-
munoprecipitation assay buffer (50 mmol/l Tris–Cl, pH 7.4, 150 mmol/l 
NaCl, 0.25% NaDeoxycholate, 1% NP-40 (IGEPAL), 1 mmol/l EDTA, 
1× Protease Inhibitor Cocktail). The nuclear lysate was quantified using a 
BCA assay (Life Technologies). Polyacrylamide gels (10–20% Tris Glycine, 
BioRad) were loaded with 250 µg of protein per sample and run at 115 V 
for 1.5 hours and then transferred to polyvinylidene difluoride membrane 
using a semi-dry blotting apparatus at 75 V for 1.5 hours. The membrane was 
blocked in 5% dry milk in TBST (20 mmol/l Tris, pH 7.5, 150 mmol/l NaCl, 
0.1% Tween) and then probed for 48 hours at 4 °C with primary a rat anti-
HA antibody conjugated to horseradish peroxidase at 1:100–250 (Roche, 
12013819001). The western was incubated with the ECL Plus Reagent 
(Amersham, Marlborough, MA, RPN2133) for 15 minutes and imaged on 
a Storm 860 imager (Molecular Dynamics, Marlborough, MA). Images were 
not altered.
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For the experiments in Figure  4e, mouse brains were harvested and 
immediately snap frozen at −80 °C. Proteins were extracted using the 
CelLytic NuCLEAR Extraction Kit (Sigma) according to the manufacturer’s 
instructions. Protein concentration was determined utilizing the BCA 
Protein Assay kit (Pierce). About 20 µg of protein were separated on a 
Novex 4–12% Bis-Tris gel (Life Technologies) using 3-(N-morpholino)
propanesulfonic acid buffer and BOLT Antioxidant as described by the 
manufacturer. Using the Mini Trans-Blot Cell (BioRad), proteins were 
transferred onto nitrocellulose membranes, in transfer buffer (25 mmol/l 
Tris, 192 mmol/l glycine, 20% (v/v) methanol), overnight at 30 V in the 
cold room. After transfer, protein loading was evaluated using Ponceau 
S staining. Membranes were then blocked with 5% dry milk in TBST (20 
mmol/l Tris, pH 7.5, 150 mmol/l NaCl, 0.1% Tween) and probed with anti-
Ube3a antibody (Sigma, E8655, 1:1,000 dilution). After incubation with goat 
anti-mouse horseradish peroxidase (Santa Cruz, Biotechnology, Santa Cruz, 
CA, SC2055, 1:2,500 dilution), chemiluminescence was detected using the 
ECL Prime Western Blotting Detection Reagent (Amersham, RPN2232).
SUPPLEMENTARY MATERIAL
Figure S1. Sequence of proteins and reporters used in this study.
Figure S2. TAT-ATFs protein purification.
Figure S3. High-resolution images of Ube3a activation by TAT-S1 but 
not TAT-R6.
Table S1. DNA binding sequence and recognition helices of the zinc 
finger arrays used in this study.
Table S2. Primers used in this study.
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